Back to today’s briefing

Story perspectives

Novo Nordisk Sues Hims & Hers Over Wegovy Patent

2/10/2026

39 5 Full Breakdown

Summary

Story summary

Novo Nordisk filed a lawsuit against Hims & Hers alleging patent infringement on semaglutide, Wegovy’s active ingredient.
The filing followed Hims & Hers' brief plan to market a compounded Wegovy at a lower cost, prompting safety concerns.
Hims & Hers said it would stop sales after FDA backlash and Novo Nordisk's legal threats.
The FDA referred Hims & Hers to the Department of Justice for potential federal-law violations.

History

Historical Context

The Patent Act of 1952 established a comprehensive framework for patent protection in the U.S., building on earlier laws dating back to 1790. This act introduced the requirement for non-obviousness and codified patent law into Title 35 of the U.S. Code. The ongoing legal disputes, such as Novo Nordisk's lawsuit against Hims & Hers over semaglutide, reflect tensions between innovation and market access in the pharmaceutical industry.

1 of 2

Story summary

Novo Nordisk filed a lawsuit against Hims & Hers alleging patent infringement on semaglutide, Wegovy’s active ingredient.
The filing followed Hims & Hers' brief plan to market a compounded Wegovy at a lower cost, prompting safety concerns.
Hims & Hers said it would stop sales after FDA backlash and Novo Nordisk's legal threats.
The FDA referred Hims & Hers to the Department of Justice for potential federal-law violations.

1 / 2